靶向GPRC5D治疗多发性骨髓瘤的研究进展  

Research progress in targeting GPRC5D for the treatment of multiple myeloma

作　　者：安嘉颖 潘萌萌 欧阳皖雁 糜坚青[1] An Jiaying;Pan Mengmeng;Ouyang Wanyan;Mi Jianqing(National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院血液科,上海血液学研究所,组学与疾病全国重点实验室,国家转化医学研究中心,上海200025

出　　处：《中华血液学杂志》2024年第9期883-888,共6页Chinese Journal of Hematology

基　　金：国家自然科学基金(82070227)。

摘　　要：多发性骨髓瘤(MM)是一类由浆细胞克隆性异常增殖引起的恶性疾病,发病率占血液肿瘤的10%。近年来,随着靶向药物的研发和应用,MM的治疗取得了显著进展,但患者仍面临复发耐药的挑战。G蛋白偶联受体C类第5组成员D(GPRC5D)独立于B细胞成熟抗原(BCMA),在MM细胞中高表达,是继BCMA后极具潜力的新靶点。本文在重点介绍靶向GPRC5D治疗MM的疗效和安全性的同时,对靶向GPRC5D疗法的耐药复发机制及与BCMA双靶点序贯或联合治疗的时机也提出了展望。Multiple myeloma(MM)is a malignant disease caused by the abnormal clonal proliferation of plasma cells,accounting for 10% of all hematologic cancers.In recent years,with the development and application of targeted drugs,a significant progress has been observed in the treatment methods of MM,but patients still face the challenges of relapse and drug resistance.Moreover,G protein-coupled receptor class C Group 5 member D(GPRC5D)is highly expressed in MM cells independently of B cell maturation antigen(BCMA)and is a highly promising target following BCMA.Aside from emphasizing the therapeutic efficacy and safety of targeting GPRC5D for the treatment of MM,this study also provides a prospective view on the mechanisms of drug resistance and relapse associated with GPRC5D-targeted therapies,as well as the timing of sequential or combined treatment strategies involving the dual targeting of both GPRC5D and BCMA.

关 键 词：异常增殖 多发性骨髓瘤 疗效和安全性 G蛋白偶联受体 血液肿瘤 克隆性 B细胞成熟抗原 双靶点 

分 类 号：R733.3[医药卫生—肿瘤]